



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Zelsuvmi (berdazimer topical gel) Page: 1 of 2

Effective Date: 1/13/2025 Last Review Date: 11/26/2024

Applies to:  Illinois  New Jersey  Maryland  
 Florida Kids  Pennsylvania Kids  Virginia

### Intent:

The intent of this policy/guideline is to provide information to the prescribing practitioner outlining the coverage criteria for Zelsuvmi under the patient's prescription drug benefit.

### Description:

#### FDA-Approved Indication

Zelsuvmi is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.

### Applicable Drug List:

Zelsuvmi

### Policy/Guideline:

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is being prescribed for the treatment of molluscum contagiosum (MC)

#### **AND**

- The patient is 1 year of age or older

#### **AND**

- The requested drug will not be used on the same lesions for more than 12 weeks

#### **AND**

- The request is NOT for continuation of therapy

#### **OR**

- The request is for continuation of therapy

#### **AND**

- The patient has achieved or maintained a positive clinical response to the requested drug (e.g., clearance of or reduction in the number of lesions with prior treatment)

#### **AND**

- If additional quantities are being requested, then the requested drug is being prescribed to treat a number of lesions that requires more than 1 carton per 28 days.

### Approval Duration and Quantity Restrictions:

**Initial Approval:** 3 Months

**Renewal Approval:** 12 Months

**Quantity Level Limit:** 1 carton per 28 days;

For a number of lesions requiring more than 1 carton per 28 days: 2 cartons per 28 days



AETNA BETTER HEALTH®  
Coverage Policy/Guideline

Name: Zelsuvmi (berdazimer topical gel) Page: 2 of 2

Effective Date: 1/13/2025 Last Review Date: 11/26/2024

Applies to:  Illinois  New Jersey  Maryland  
 Florida Kids  Pennsylvania Kids  Virginia

### References:

1. Zelsuvmi [package insert]. Wilmington, DE: EPIH SPV, LLC; January 2024.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed July 3, 2024.
3. Centers for Disease Control and Prevention. Molluscum contagiosum, May 13, 2024. <https://www.cdc.gov/poxvirus/molluscum-contagiosum/>. Accessed July 3, 2024.
4. American Academy of Dermatology Association. Molluscum contagiosum, November 6, 2023. <https://www.aad.org/public/diseases/a-z/molluscum-contagiosum-overview>. Accessed July 3, 2024.
5. Hebert AA, Bhatia N, Del Rosso JQ. Molluscum contagiosum: epidemiology, considerations, treatment options, and therapeutic gaps. *J Clin Aesthet Dermatol*. 2023 Aug;16(8 Suppl 1):S4-S11.
6. Sugarman JL, Hebert A, Browning JC, et al. Berdazimer gel for gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. *J Am Acad Dermatol*. Published online October 5, 2023
7. U.S. Department of Health & Human Services. Burn Triage and Treatment – Thermal Injuries. Chemical Hazards Emergency Medical Management. June 7, 2024. Available at: <https://chemm.hhs.gov/burns.htm>. Accessed July 3, 2024.